VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE
· Real-Time Price · USD
0.40
-1.04 (-72.22%)
At close: Jul 30, 2025, 3:59 PM
VYNE Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -8.61M | -12.02M | -12.16M | -9.41M | -6.25M | -6.19M | -6.58M | -10.06M | -5.62M | -9.95M | -9.46M | -8.48M | 4.67M | -11.57M | -21.29M | -19.92M | -20.55M |
Depreciation & Amortization | 6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -155K | 171K | 12K | 44K | 26K | 28K | 28K | 27K |
Stock-Based Compensation | 763K | 699K | 734K | 885K | 985K | 710K | 863K | 876K | 856K | 1.07M | 1.17M | 1.16M | 893K | 1.33M | 2.4M | 1.9M | 2.44M |
Other Working Capital | -37K | -23K | 69K | -35K | -34K | -957K | 585K | -263K | -68K | 2.62M | n/a | 9.41M | -9.73M | -1.75M | -2.76M | 3.53M | 404K |
Other Non-Cash Items | -324K | -541K | 2.75M | -433K | 2.1M | -1.05M | 289K | 985K | 778K | 280K | -48K | 40K | -12.99M | 1.3M | 1.43M | -84K | -174K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 93K | 1.43M | n/a | n/a |
Change in Working Capital | -3.29M | 2.87M | 3.42M | 655K | -1.94M | 595K | 569K | -392K | -712K | 4.88M | 950K | -964K | -2.59M | -1.2M | -1.55M | 1.82M | 5.7M |
Operating Cash Flow | -11.46M | -9M | -8.51M | -8.48M | -7.98M | -5.14M | -5.15M | -9.57M | -5.48M | -3.88M | -7.13M | -8.22M | -9.97M | -10.02M | -17.54M | -16.26M | -12.55M |
Capital Expenditures | n/a | -117K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -5M | n/a | n/a | 5M | -935K | -86K | 16.69M | 16.69M | n/a | n/a | n/a | n/a |
Purchase of Investments | -13.77M | -10.04M | -28.42M | -6.88M | -15.17M | -62.35M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 33.6M | 22.9M | 23.6M | 25.9M | 11.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.03M | n/a |
Other Investing Acitivies | n/a | -117K | n/a | n/a | n/a | 5M | n/a | n/a | n/a | -1.02M | n/a | -16.69M | 16.69M | n/a | n/a | n/a | n/a |
Investing Cash Flow | 19.83M | 12.74M | -4.82M | 19.02M | -3.57M | -62.35M | n/a | n/a | 5M | -935K | -86K | n/a | 16.69M | n/a | n/a | 1.03M | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -360K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -87K | -132K | -2K | -3K | -4K | -2K | -47K | -5K | -13K | 209K | -26K | n/a | -25K | -9K | -36.44M | -129K | 376K |
Financial Cash Flow | -87K | -132K | -2K | -3K | -4K | 82.66M | -47K | -5K | -217K | 208K | -26K | -61K | 1.53M | -38K | -33.56M | -129K | 73.5M |
Net Cash Flow | 8.28M | 3.61M | -13.34M | 10.54M | -11.55M | 15.17M | -5.2M | -9.58M | -695K | -4.6M | -7.24M | -8.29M | 8.24M | -10.06M | -51.1M | -15.36M | 60.95M |
Free Cash Flow | -11.46M | -9.12M | -8.51M | -8.48M | -7.98M | -5.14M | -5.15M | -9.57M | -5.48M | -3.88M | -7.13M | -8.22M | -9.97M | -10.02M | -17.54M | -16.26M | -12.55M |